Biodistribution of 6-[211At]astato-2-methyl-1,4-naphthoquinol bis(diphosphate salt) and 211At- in mice with a transplanted rectal adenocarcinoma.
6-[211At]astato-MNDP is currently being investigated as a potential high LET endoradiotherapeutic drug. Biodistribution and whole-body radiation retention studies have been carried out with 6-[211At]astato-MNDP and 211At- in a murine rectal tumour model; results indicate that the 211At-C bond in the compound is metabolically stable for at least 6 h. The Mean Biological Concentration of 6-[211At]astato-MNDP in tumour tissue ranged from 170-253% over an initial 12 h period; this was higher than that observed for the [211At]astatide anion. Conversely, the uptake of compound into radiobiologically critical organs was significantly lower.
D000230:Adenocarcinoma / Q000378:metabolism*; D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism*; D001246:Astatine / Q000378:metabolism*; D005260:Female; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D012004:Rectal Neoplasms / Q000378:metabolism*; D014018:Tissue Distribution; D014812:Vitamin K / Q000031:analogs & derivatives* / Q000378:metabolism; D024483:Vitamin K 3 / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D014812:Vitamin K; D024483:Vitamin K 3; C033669:astato-2-methyl-1,4-naphthoquinol diphosphate; D001246:Astatine